Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Benzinga Pro's 5 Stocks To Watch Today

GOOG, CNP, HAS, MAT, SAGE

Each day, the Benzinga Pro news team highlights several stocks with Trading Idea potential. Be the first to see them by becoming a Benzinga Pro user!

Hasbro, Inc. (NASDAQ: HAS) stock lost nearly 7 percent early Monday morning after reporting its first quarter results. The toymaker earned 10 cents per share in the first quarter on revenue of $716.34 million versus expectations of 34 cents per share and $819.4 million. Shares of rival toymaker Mattel, Inc. (NASDAQ: MAT) traded lower by more than 5 percent in sympathy.

Alphabet Inc (NASDAQ: GOOG) (NASDAQ: GOOGL) is scheduled to report its first quarter results after Monday's market close and is expected to earn $9.33 per share on revenue of $30.31 billion.

McDermott International Inc (NYSE: MDR) gained more than 17 percent after the UK-based offshore oil service company Subsea 7 made an unsolicited bid to buy McDermott for $7 per share. However, the acquisition offer is contingent on McDermot terminating its pending merger with Chicago Bridge & Iron Company (NYSE: CBI). Accordingly, shares of Chicago Bridge & Iron lost more than 15 percent early Monday morning.

Vectren Corp (NYSE: VVC) moved up 5 percent after the company agreed to be acquired by CenterPoint Energy, Inc. (NYSE: CNP) for $72 per share.

SAGE Therapeutics Inc (NASDAQ: SAGE) was trading higher by 2 percent after the clinical-stage biopharmaceutical company said it submitted a New Drug Application (NDA) to the FDA for its lead product candidate called SAGE-547, which is used for the treatment of postpartum depression.

Related Links:

24 Stocks Moving In Monday's Pre-Market Session

A Peek Into The Markets: US Stock Futures Flat Ahead Of Earnings



Get the latest news and updates from Stockhouse on social media

Follow STOCKHOUSE Today